Abstract
Impairment in oxidative stress/antioxidant balance is an important trigger for a variety of diseases. As an antioxidant molecule on high-density lipoprotein (HDL), paraoxonase (PON1) contributes to the antioxidant mechanisms by removing oxidised lipids both on HDL and low-density lipoprotein (LDL). In this chapter, we will document and evaluate the results of our studies on healthy, atheroscleoric and diabetic cases which showed that (a) PON1, superoxide dismutase (SOD) and arylesterase probably work in a collaboration against oxidative stress, especially superoxide radical scavenging; (b) PON1 and SOD activities concomitantly decrease with the oxidative stress & severity of disease (higher HbA1c values in diabetics, more diseased vessels in atherosclerosis) while catalase (CAT) acts the opposite way; (c) Since PON1 activity and erythrocte thiobarbituric acid reactive substances (eTBARS) levels are affected by traditional risk factors (hypertension, aging and gender), determination of arylesterase activity might be a better indicator of antioxidant activity of PON1; (d) SOD activity has the greatest variability in regard to PON1 phenotype therefore it’s important to define the PON1 polymorphism as well as PON1, arylesterase and other antioxidant enzyme activities
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Adkins S., Gan K.N., Mody M., LaDu B.N., 1993, Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase; glutamine or arginine at position 191, for respective A or B allozymes. Am J Hum Genet 52: 598–608.
Agachan B., Yılmaz H., Ergen H.A., Karaali Z.E., Isbir T., 2005, Paraoxonase (PON1) 55 and 192 polymorphism and its effects to oxidant-antioxidant system in Turkish patients with type 2 diabetes mellitus. Physiol Res 54: 287–93.
Aguirre F., Martin I., Grinpson D., Ruiz M., Hager A., De Paoli T., Ihlo J., Farach H.A., Poole C.P., 1998, Oxidative damage, plasma antioxidant capacity and glycemic control in elderly NIDDM patients. Free Rad Biol Med 24: 580–5.
Arai K., Iızuka S., Tada Y., Oikawa K., Taniguchi N., 1987, Increase in the glycosylated form of erythrocyte Cu-Zn superoxide dismutase in diabetes and close associaton of the nonenzymatic glucosylation with the enzyme activity. Biochim Biophys Acta 924: 292–6.
Aviram M., 1996, Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis and the atherogenicity of antioxidants. Eur J Clin Biochem 34: 599–608.
Aviram M., 1999, Does paraoxonase play a role in susceptibility to cardiovascular disease. Mol Med Today 5: 381–6.
Aviram M., Rosenblat M., 2005, Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipidol 16: 393–9.
Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parma S.L., LaDu B.N., 1998, Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 101(8): 1581–90.
Aviram M., Rosenblat M., Scott B., Drogul J., Sorenson R., Bisgaier C.L., Newton R.S., La Du B., 1999, Human serum paraoxonase (PON1) is inactivated by oxidised low density lipoprotein and preserved by antioxidants. Free Rad Biol Med 26(7/8): 892–904.
Azarsiz E., Kayikcioglu M., Payzin S., Sozmen E.Y., 2003, PON1 Activities and Oxidative Markers of LDL in Patients With Angiographically Proven Coronary Artery Disease. Int J Cardiol 91: 43–51.
Chisolm G.M., Steinberg D., 2000, The oxidative modification hypothesis of atherogenesis: an overview. Free Rad Biol Med 28(12): 1815–26.
Durrington P.N., Mackness B., Mackness M.I., 1999, Role of HDL in preventing atherogenic modification of LDL. Atherosclerosis 146 (suppl): 813.
Ferre N., Camps J., Fernandez-Ballart J., Arija V., Murphy M.M., Ceruleo S., Biarnes E., Vilella E., Tous M., Joven J., 2003, Regulation of serum paraoxonase activity by genetic, nutritional and lifestyle factors in the general population. Clin Chem 49(9): 1491–7.
Freeman B.A., Crapo J.D., 1982, Biology of disease: free radicals and tissue injury. Lab Invest 47(5): 412–25.
Graner M., James R.W., Kahri J., Nieminen M.S., Syvanne M., Taskinen M.R., 2006, Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J Am Coll Cardiol 47(2): 2429–35.
Henriksen T., Mahoney E.M., Steinberg D., 1981, Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells; recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci USA 78: 6499–503.
Jaouad L., Milochevitch C., Khalil A., 2003, PON1 activity is reducued during HDL oxidation and is an indicator of HDL antioxidant capacity. Free Rad Res 37(1): 77–83.
Jarvik G.P., Rozek L.S., Brophy V.H., Hatsukami T.S., Richter R.J., Schellenberg G.D., Furlong C.E., 2000, Paraoxonase phenotype is a beter predictor of vascular disease than is PON192 or PON 55 genotype. Arterioscler Thromb Vasc Biol 20: 2441–7.
Jialal I., Devaraj S., 1996, Low density lipoprotein oxidation, antioxidants and atherosclerosis. A clinical biochemistry perspective. Clin Chem 42(4): 498–506.
Kaplan M., Aviram M., 1999, Oxidized low density lipoprotein: atherogenic and proinflamatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase. Clin Chem Lab Med 37(8): 777–87.
Karabina S.A.P., Lehner A.N., Frank E., Parthasarathy S., Santanam N., 2005, Oxidative inactivation of paraoxonase- implications in diabetes mellitus and atherosclerosis. Biochim Biophys Acta 1725: 213–21.
La Du B.N., Adkins S., Kuo C.L., Lipsig D., 1993, Studies on human serum paraoxonase/arylesterase. Chem Biol Interact 87: 25–34.
Lankin V.Z., Vikhert A.M., Kosykh V.A., Tikhaze A.K., Galakhov L.E., Orekhov A.N., 1984, Enzymatic detoxication of superoxide anion radicals and lipoperoxides in intima and media of atherosclerotic aorta. Biomed Biochim Acta 43: 797–802.
Laplaud R.M., Dantoine T., Chapman M.J., 1998, Paraoxonase as a risk marker for cardiovascular disease: facts and hypotheses. Clin Chem Lab Med 36(7): 431–41.
Mackness B., Davies G.K., Turkie W., Lee E., Roberts D.H., Roberts C., Durrington P.N., Mackness M.I., 2001, Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype. Arterioscler Thromb Vasc Biol 21: 1451–7.
Mackness B., Durrington P., McElduff P., Yarnell J., Azam N., Watt M., Mackness M., 2003, Low paraoxonase activity predicts coronary events in the Caerphilly prospective study. Circulation 107: 2775–9.
Mackness B., Durrington P.N., Mackness M.I., 1998, Human serum paraoxonase. Gen Pharm 31(3): 329–36.
Mackness M.I., Mackness B., Durrington P.N., Connelly P.W., Hegele R.A., 1996, Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 7: 69–76.
Mackness M.I., Mackness B., Durrington P.N., 2002, Paraoxonase and coronary heart disease. Atherosclerosis suppl 3: 49–55.
Mates J.M., Perez-Gomez C., De Castro I.N., 1999, Antioxidant enzymes and human diseases. Clin Biochem 32 (8): 595–603.
Maxwell S.R.J., Thomason H., Sandler D., Leguen C., Baxter M.A., Thorpe G.H.G., Jones A.F., Barnett A.H., 1997, Poor glycaemic control is associated with reduced serum free radical scavenging (antioxidant) activity in non-insulin-dependent diabetes mellitus. Ann Clin Biochem 34: 638–44.
Ng C.J., Shih D.M., Hama S.Y., Villa N., Navab M., Reddy S.T., 2005, The paraoxonase gene family and atherosclerosis. Free Rad Biol Med 38: 153–63.
Nguyen S.D., Sok D.E., 2003, Oxidative inactivation of paraoxonase-1, an antioxidant protein and its effect on antioxidant action. Free Rad Res 37(12): 1319–30.
Nguyen S.D., Sok D.E., 2006, Preferable stimulation of PON1 arylesterase activity by phosphatidyl-cholines with unsaturated acyl chains or oxidized acyl chains at sn-2 position. Biochim Biophys Acta 1758: 499–508.
Parthasarathy S., Santanam N., Ramachandran S., Meilhac O., 1999, Oxidants and antioxidants in atherogenesis; an appraisal. J Lipid Res 40: 2143–57.
Rosenblat M., Oren R., Aviram M., 2006, Lysophosphatidylcholine (LPC) attenuates macrophage mediated oxidation of LDL. Biochem Biophys Res Comm 344: 1271–7.
Ross R., 1999, Atherosclerosis: an inflammatory disease. NEJM 340(2): 115–26.
Rozenberg O., Rosenblat M., Coleman R., Shih D.M., Aviram M., 2003, Paraoxonase deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Rad Biol Med 34(6): 774–84.
Sanghera D.K., Saha N., Aston C.E., Kamboh M.I., 1997, Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 17: 1067–73.
Sangvanich P., Mackness B., Gaskill S., Durrington P.N., Mackness M.I., 2003, The effect of HDL on the formation of lipid/protein conjugates during in vitro oxidation of LDL. Biochem Biophys Res Comm 300: 501–6.
Serrato M., Marian A.J., 1995, A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 96: 3005–8.
Shih D.M., Gu L., Hama S., Xia Y., Navab M., Fogelman A.M., Lusis A.J., 1996, Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 97(7): 1630–9.
Sozmen E.Y., Kerry Z., Uysal F., Yetik G., Yasa M., Ustunes L., Onat T., 2000, Antioxidant enzyme activities and total nitrite/nitrate levels in the collar model: effect of nicardipine. Clin Chem Lab Med 38(1): 21–5.
Sozmen E.Y., Sozmen B., Delen Y., Onat T., 2001a, Catalase/superoxide dismutase and catalase/ paraoxonase ratios may implicate poor glycemic control. Arch Med Res 32: 283–7.
Sozmen E.Y., Sozmen B., Girgin F.K., Delen Y., Azarsiz E., Erdener D., Ersoz B., 2001b, Antioxidant enzymes and paraoxonase show co-activity in preserving LDL from oxidation. Clin Exp Med 1: 195–9.
Steinberg D., 1997, Oxidative modification of LDL and atherogenesis. Circulation 95: 1062–71.
Van Lenten B.J., Wagner A.C., Navab M., Fogelman A.M., 2001, Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6. J Biol Chem 19; 276 (3): 1923–9.
Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Fauli F.K., Fogelman A.M., Navab M., 1995, Protective effect of high density lipoprotein associated paraoxonase-inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96: 2882–91.
Wheeler J.G., Keavney B.D., Watkins H., Collins R., Danesh J., 2004, Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta analysis of 43 studies. Lancet 363: 689–95.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer
About this chapter
Cite this chapter
Sozmen, E.Y., Sagin, F.G., Kayikcioglu, M., Sozmen, B. (2008). Oxidative Stress & Antioxidants and PON1 in Health and Disease. In: Mackness, B., Mackness, M., Aviram, M., Paragh, G. (eds) The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism. Proteins And Cell Regulation, vol 6. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-6561-3_4
Download citation
DOI: https://doi.org/10.1007/978-1-4020-6561-3_4
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-6560-6
Online ISBN: 978-1-4020-6561-3
eBook Packages: MedicineMedicine (R0)